FIELD OF THE DISCLOSURE

The present disclosure relates to a composition containing apomorphine and a divalent metal cation, a process for preparing this composition, a composition obtainable by this process, and the use of said compositions as a medicament, in particular for diagnosing, preventing and treating Parkinson's disease.

BACKGROUND OF THE DISCLOSURE

Apomorphine (systematical name: (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol) is used as an emetic, as an antidote and for the diagnosis and the treatment of the Parkinson's disease. In case of the treatment of Parkinson's disease, apomorphine is administered by infusions or by injections subcutaneously (s.c.). The commercially available product APO-go® used for the treatment of Parkinson's disease is provided with a pH of 3 to 4.

However, the administration of apomorphine to patients in need thereof can lead to the side effect of coagulative necrosis.

SUMMARY OF THE DISCLOSURE

A technical problem underlying the present disclosure can be seen in avoiding the above disadvantage, i.e. coagulative necrosis.

This has been achieved by the composition according to an aspect of the present disclosure, which comprises apomorphine and a divalent metal cation in a molar ratio of 2 or less.

A further advantage of the composition is that it shows a relatively high stability with respect to apomorphine.

